Climb Bio Files Supplemental Proxy for 2025 Meeting
Ticker: CLYM · Form: DEFA14A · Filed: May 23, 2025 · CIK: 1768446
Sentiment: neutral
Topics: proxy-statement, annual-meeting, supplemental-filing
TL;DR
Climb Bio's proxy supplement is out for the 2025 shareholder meeting. No fee.
AI Summary
Climb Bio, Inc. (formerly Eliem Therapeutics, Inc.) is filing a supplemental proxy statement for its 2025 Annual Meeting of Stockholders. The filing, dated May 23, 2025, is a definitive additional material and does not require a filing fee. The company is incorporated in Delaware and its fiscal year ends on December 31.
Why It Matters
This filing provides additional information to shareholders regarding the upcoming 2025 Annual Meeting, ensuring they have the latest details for their voting decisions.
Risk Assessment
Risk Level: low — This is a routine filing for an annual meeting and does not appear to contain any new or unusual financial or strategic information.
Key Players & Entities
- Climb Bio, Inc. (company) — Registrant
- Eliem Therapeutics, Inc. (company) — Former company name
- 2025 (date) — Annual Meeting Year
- May 23, 2025 (date) — Filing Date
FAQ
What is the purpose of this DEFA14A filing?
This filing is a supplemental proxy statement for Climb Bio, Inc.'s 2025 Annual Meeting of Stockholders, providing definitive additional materials.
What was Climb Bio, Inc. formerly known as?
Climb Bio, Inc. was formerly known as Eliem Therapeutics, Inc.
When is the 2025 Annual Meeting of Stockholders?
The filing is a supplement to the proxy statement for the 2025 Annual Meeting of Stockholders.
Is there a filing fee associated with this document?
No, the filing indicates that no fee is required for this document.
What is the Standard Industrial Classification code for Climb Bio, Inc.?
The Standard Industrial Classification code for Climb Bio, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form DEFA14A (Form DEFA14A) was filed with the SEC on May 23, 2025 regarding Climb Bio, Inc. (CLYM).